Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK1265744

Known as: GSK744 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Pyridones

Narrower (1)

cabotegravir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
BACKGROUND Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2015
Highly Cited
2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised…
BACKGROUND In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
Background:GSK1265744 (744) is an HIV-1 integrase inhibitor in clinical development as a long-acting (LA) injectable formulation… Expand
Highly Cited
2014
Highly Cited
2014
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
Objective:Pharmacokinetics, safety, and tolerability of GSK1265744 (744) and rilpivirine (RPV) (TMC278) were assessed after… Expand
Highly Cited
2014
Highly Cited
2014
Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
ABSTRACT GSK1265744 is a new HIV integrase strand transfer inhibitor (INSTI) engineered to deliver efficient antiviral activity… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2014
2014
Long-acting HIV drugs advanced to overcome adherence challenge
  • E. Dolgin
  • Nature Medicine
  • 2014
    • Corpus ID: 205378175
BOSTON — The results from a particular drug trial presented here last month at the annual Conference on Retroviruses and… Expand
Highly Cited
2014
Highly Cited
2014
Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
Keeping HIV at Bay? Preexposure prophylaxis involving daily doses of drugs can, with variable success rates, interrupt HIV… Expand
Highly Cited
2013
Highly Cited
2013
Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
Abstract Background: GSK1265744 is an HIV integrase strand transfer inhibitor selected for clinical development. Objective: This… Expand
Highly Cited
2013
Highly Cited
2013
Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).
We report herein the discovery of the human immunodeficiency virus type-1 (HIV-1) integrase inhibitors dolutegravir (S/GSK1349572… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 3
Highly Cited
2013
Highly Cited
2013
Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
ABSTRACT Dolutegravir (DTG) and GSK1265744 are HIV integrase inhibitors (INIs) in clinical development. The oral formulation of… Expand
  • table 1
  • table 3
  • figure 1
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE